Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for VRX
19.71
+0.03 (0.15%)
Dec 15 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 19.20 - 20.39
52 week 8.31 - 22.81
Open 19.70
Vol / Avg. 23.79M/23.74M
Mkt cap 6.88B
P/E 5.05
Div/yield     -
EPS 3.90
Shares 348.26M
Beta -0.22
Inst. own 57%
Feb 26, 2018
Q4 2017 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 14, 2017
Valeant Pharmaceuticals International Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference
Nov 29, 2017
Valeant Pharmaceuticals International Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference
Nov 14, 2017
Valeant Pharmaceuticals International Inc at Stifel Healthcare Conference - Webcast
Nov 7, 2017
Q3 2017 Valeant Pharmaceuticals International Inc Earnings Release
Nov 7, 2017
Q3 2017 Valeant Pharmaceuticals International Inc Earnings Call - Webcast
Oct 4, 2017
Valeant Pharmaceuticals International Inc at Deutsche Bank Leveraged Finance Conference - Webcast
Sep 25, 2017
Valeant Pharmaceuticals International Inc at Cantor Fitzgerald Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 58.58% -24.89%
Operating margin 1.67% -5.85%
EBITD margin - 41.49%
Return on average assets 12.76% -5.21%
Return on average equity 112.73% -53.16%
Employees 21,500 -
CDP Score - D

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Paul S. Herendeen Chief Financial Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Christina Ackermann Executive Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Thomas J. Appio Executive Vice President, Company Group Chairman, International
Age: 55
Bio & Compensation  - Reuters
William D. Humphries Executive Vice President, Company Group Chairman, Dermatology
Age: 50
Bio & Compensation  - Reuters
Thomas W. Ross Sr Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
Richard U. DeSchutter Independent Director
Age: 76
Bio & Compensation  - Reuters
Fredric N. Eshelman Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
D. Robert Hale Independent Director
Age: 32
Bio & Compensation  - Reuters
Argeris N. Karabelas Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters